Prostate cancer is the 2nd most common male cancer in the world.
In 2022, there were nearly 1.5 million new cases of prostate cancer and 0.4 million patients died of this disease.
Many lives could be saved, if the cancer had been diagnosed earlier and more accurately.
Unfortunately, the current prostate cancer diagnostics are inaccurate, invasive and require specialised equipment. These limitations result in cancer being diagnosed often too late to allow effective treatment.
We believe that prostate cancer diagnostic can be and should be radically improved.
To do so, MUGENBIO develops the next-generation diagnostic platform, which aims to integrate three key innovations:
The MUGENBIO's diagnostic platform will immensely improve prostate cancer diagnostic by bringing number of benefits to patients, including:
Copyright © 2024 MUGENBIO - All Rights Reserved.
Powered by GoDaddy